{
  "ptid_time": "114_S_1106_2012-12-06",
  "img_path": "/data/qiuhui/data/adni/images/114_S_1106/2012-12-06/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 47,728 mm³, 29.1% above the reference mean. With a Z-score of 0.79 (78.4th percentile), this represents normal volume ; hippocampal volume measures 5,140 mm³, 20.9% below the reference mean. With a Z-score of -1.67 (4.7th percentile), this represents moderate atrophy; whole brain volume measures 802,561 mm³, 13.5% below the reference mean. With a Z-score of -1.62 (5.2th percentile), this represents moderate atrophy; entorhinal cortex volume measures 2,453 mm³, 29.2% below the reference mean. With a Z-score of -1.57 (5.8th percentile), this represents moderate atrophy; fusiform gyrus volume measures 13,465 mm³, 16.4% below the reference mean. With a Z-score of -1.23 (10.9th percentile), this represents mild atrophy; middle temporal gyrus volume measures 12,890 mm³, 28.5% below the reference mean. With a Z-score of -2.54 (0.6th percentile), this represents significant atrophy. ",
  "text_data": "Age is 80.0 years. Gender is Female. Education: 18 years. MMSE: 27.0. MoCA: 21.0. Logical Memory: 3.0. APOEε4 alleles: 0.0. ",
  "true_diagnosis": "Diagnosis: AD.",
  "gpt_diagnosis": "**Reasoning:** The patient exhibits significant atrophy in key Alzheimer's-related regions (hippocampus, entorhinal cortex, middle temporal gyrus) alongside mild-to-moderate whole-brain atrophy. The MMSE (27) is borderline normal, but the MoCA (21) suggests mild cognitive impairment. The absence of APOE4 does not rule out neurodegeneration.  \n\n**Diagnosis:** **Mild Cognitive Impairment (MCI)** (likely amnestic subtype given hippocampal/entorhinal atrophy).  \n\n**Confidence:** **Medium** (imaging strongly supports MCI, but clinical scores are borderline; lack of detailed functional history limits certainty).  \n\n*Note:* Progression to dementia (likely Alzheimer’s) is probable given the extent of temporal lobe atrophy, but current MoCA does not meet dementia thresholds. Follow-up with CSF biomarkers or amyloid PET could clarify.",
  "timestamp": "2025-07-26T11:44:44.591019"
}